Emilio Pechuan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emilio Pechuan has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Alba Toll
Maresme Health Consortium
2 shared publications Alfonso Gonzalez-Valderrama
1 shared publication- Amira Trabsa
Centro de Investigación Biomédica en Red, Área de Salud Mental (CIBERSAM), Madrid, Spain
1 shared publication Anil K. Malhotra
1 shared publication- Anna Mané
Hospital del Mar
1 shared publication Annie Blazer
1 shared publication
Latest Publications
- 9 May 2026
- Published by Springer Nature in Archives of Women's Mental Health
- Vol. 29 (3) , 74
Women with first-episode psychosis: diagnostic stability and clinical trajectories
Purpose The aim of this study was to assess the influence of sex on diagnostic stability in first-episode psychosis during the first year of follow-up. Methods This was a prospective, observational study of 256 patients with FEP, of whom 188 (73.4%) completed the 1-year follow-up. Patients were consecutively recruited at a specialized early intervention program. Comprehensive psychiatric evaluations and the Structured Clinical Interview for DSM-IV-TR Axis I disorders were performed at baseline and follow-up. Diagnoses were grouped into affective and non-affective psychoses. Univariate and multivariate logistic regression analyses were conducted to identify predictors of diagnostic shift, with a particular focus on sex. Results At one-year follow-up, 48.9% of patients experienced some form of diagnostic change. Specifically, 14.4% shifted from non-affective to affective psychosis. Female sex was the only independent predictor of diagnostic shift (OR = 0.30; 95% CI = 0.10–0.87; p = 0.027). No other clinical or demographic variables were significantly associated with diagnostic change. Conclusion Female FEP patients were significantly more likely to experience a diagnostic shift toward affective psychosis during the first year of follow-up. These findings highlight the importance of considering sex differences in clinical presentation at illness onset to improve diagnostic accuracy, optimize treatment strategies, and enhance long-term outcomes.
- 9 May 2026
- Published by Springer Nature in Archives of Women's Mental Health
- Vol. 29 (3) , 74
Women with first-episode psychosis: diagnostic stability and clinical trajectories
Purpose The aim of this study was to assess the influence of sex on diagnostic stability in first-episode psychosis during the first year of follow-up. Methods This was a prospective, observational study of 256 patients with FEP, of whom 188 (73.4%) completed the 1-year follow-up. Patients were consecutively recruited at a specialized early intervention program. Comprehensive psychiatric evaluations and the Structured Clinical Interview for DSM-IV-TR Axis I disorders were performed at baseline and follow-up. Diagnoses were grouped into affective and non-affective psychoses. Univariate and multivariate logistic regression analyses were conducted to identify predictors of diagnostic shift, with a particular focus on sex. Results At one-year follow-up, 48.9% of patients experienced some form of diagnostic change. Specifically, 14.4% shifted from non-affective to affective psychosis. Female sex was the only independent predictor of diagnostic shift (OR = 0.30; 95% CI = 0.10–0.87; p = 0.027). No other clinical or demographic variables were significantly associated with diagnostic change. Conclusion Female FEP patients were significantly more likely to experience a diagnostic shift toward affective psychosis during the first year of follow-up. These findings highlight the importance of considering sex differences in clinical presentation at illness onset to improve diagnostic accuracy, optimize treatment strategies, and enhance long-term outcomes.
- Open Access
- 12 March 2026
- Published by Elsevier in SSRN Electronic Journal
Neutrophil to Lymphocyte Ratio and Clozapine Response in Treatment Resistant Schizophrenia: An Individual Participant Data Meta-Analysis
Background: Treatment-resistant schizophrenia (TRS) affects one in three people with schizophrenia. Clozapine remains the only approved treatment, yet its mechanism of action is poorly understood. Converging evidence implicates immune dysregulation in TRS and suggests clozapine exerts unique immunomodulatory effects, but large-scale clinical data linking immune biomarkers – such as the neutrophil-to-lymphocyte ratio (NLR) – to clozapine response are lacking. We tested whether higher baseline NLR predicts clozapine response and whether NLR normalizes with effective treatment.Methods: We collected individual participant data – through systematic review, data repositories, and expert consultation – to conduct a meta-analysis of clozapine trials (8–24 weeks) in adults with TRS. All datasets underwent a standardized analytic pipeline. Primary analyses were logistic regression of baseline NLR predicting response (≥20% symptom improvement) and correlation between change in NLR and change in symptoms. Study-level estimates were pooled using fixed-effects meta-analysis. Meta-regressions examined sex, age, race, baseline severity, and baseline NLR. People with lived experience were involved in the interpretation of the results.Findings: Ten trials contributed 593 participants (236 [39·8%] female; mean age 37·5 years [SD 3·8]; 281 [47·4%] African ancestry). Mean baseline PANSS total was 90·1 (SD 16·2), baseline NLR 1·66 (SD 0·34), and pooled response rate 48·1%. Higher baseline NLR predicted clozapine response (OR=1·26; 95% CI 1·02–1·55; p=0·03; I2=0%). Female sex was independently associated with response (OR=1·66; 95% CI 1·14–2·41; p=0·008). NLR decreased as symptoms improved (r=−0·11; 95% CI −0·19 to −0·03; p=0·01; I2=0%). No study-level covariates moderated either association and there was no evidence of publication bias.Interpretation: Clozapine may exert its antipsychotic effects in TRS partly through normalisation of a heightened inflammatory state. Pre-treatment NLR, already routinely available from mandatory baseline blood work, could support earlier and more targeted clozapine initiation and inform development of novel anti-inflammatory strategies for TRS.PanelResearch in contextEvidence before this studyConverging evidence suggests that treatment resistant schizophrenia (TRS) is characterized by immune dysregulation and altered neuroimmune activity. Clozapine is the only drug indicated for TRS, and it is associated with unique immune mediated off target effects (e.g., benign fever, myocarditis…) and animal model data indicating immunomodulatory effects. Small studies suggest that immune effects may mediate clozapine unique antipsychotic properties in TRS, but large-scale clinical data is lacking.Added value of this studyIn this large-scale individual participant data meta-analysis we show that a higher inflammation state indicated by greater neutrophil to lymphocyte ratio (NLR) is associated with greater odds of responding to clozapine and that as symptoms improve the NLR normalizes.
- 12 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessNeutrophil to Lymphocyte Ratio and Clozapine Response in Treatment Resistant Schizophrenia: An Individual Participant Data Meta-Analysis
Background: Treatment-resistant schizophrenia (TRS) affects one in three people with schizophrenia. Clozapine remains the only approved treatment, yet its mechanism of action is poorly understood. Converging evidence implicates immune dysregulation in TRS and suggests clozapine exerts unique immunomodulatory effects, but large-scale clinical data linking immune biomarkers – such as the neutrophil-to-lymphocyte ratio (NLR) – to clozapine response are lacking. We tested whether higher baseline NLR predicts clozapine response and whether NLR normalizes with effective treatment.Methods: We collected individual participant data – through systematic review, data repositories, and expert consultation – to conduct a meta-analysis of clozapine trials (8–24 weeks) in adults with TRS. All datasets underwent a standardized analytic pipeline. Primary analyses were logistic regression of baseline NLR predicting response (≥20% symptom improvement) and correlation between change in NLR and change in symptoms. Study-level estimates were pooled using fixed-effects meta-analysis. Meta-regressions examined sex, age, race, baseline severity, and baseline NLR. People with lived experience were involved in the interpretation of the results.Findings: Ten trials contributed 593 participants (236 [39·8%] female; mean age 37·5 years [SD 3·8]; 281 [47·4%] African ancestry). Mean baseline PANSS total was 90·1 (SD 16·2), baseline NLR 1·66 (SD 0·34), and pooled response rate 48·1%. Higher baseline NLR predicted clozapine response (OR=1·26; 95% CI 1·02–1·55; p=0·03; I2=0%). Female sex was independently associated with response (OR=1·66; 95% CI 1·14–2·41; p=0·008). NLR decreased as symptoms improved (r=−0·11; 95% CI −0·19 to −0·03; p=0·01; I2=0%). No study-level covariates moderated either association and there was no evidence of publication bias.Interpretation: Clozapine may exert its antipsychotic effects in TRS partly through normalisation of a heightened inflammatory state. Pre-treatment NLR, already routinely available from mandatory baseline blood work, could support earlier and more targeted clozapine initiation and inform development of novel anti-inflammatory strategies for TRS.PanelResearch in contextEvidence before this studyConverging evidence suggests that treatment resistant schizophrenia (TRS) is characterized by immune dysregulation and altered neuroimmune activity. Clozapine is the only drug indicated for TRS, and it is associated with unique immune mediated off target effects (e.g., benign fever, myocarditis…) and animal model data indicating immunomodulatory effects. Small studies suggest that immune effects may mediate clozapine unique antipsychotic properties in TRS, but large-scale clinical data is lacking.Added value of this studyIn this large-scale individual participant data meta-analysis we show that a higher inflammation state indicated by greater neutrophil to lymphocyte ratio (NLR) is associated with greater odds of responding to clozapine and that as symptoms improve the NLR normalizes.